- Home
- DNA vs AUTL Comparison
DNA vs AUTL Comparison
Compare DNA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNA | AUTL |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United Kingdom |
| Employees | 485 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 431.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | DNA | AUTL |
|---|---|---|
| Price | $6.45 | $1.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.50 | $8.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $84.74 |
| Revenue Next Year | N/A | $65.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $5.37 | $1.15 |
| 52 Week High | $17.58 | $2.70 |
Technical Indicators
Market Signals| Indicator | DNA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 54.80 |
| Support Level | $6.26 | $1.23 |
| Resistance Level | $7.38 | $1.52 |
| Average True Range (ATR) | 0.53 | 0.09 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 46.88 | 80.25 |
Price Performance
Historical ComparisonAbout DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.